Detalles de la búsqueda
1.
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gynecol Oncol
; 161(2): 512-515, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33610319
2.
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 21(7): 957-968, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32553118
3.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Lancet Oncol
; 21(4): 531-540, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32105622
4.
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Gynecol Oncol
; 156(1): 13-22, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31708167
5.
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
Gynecol Oncol
; 155(3): 420-428, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31623857
6.
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 147(2): 283-290, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28802766
7.
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
Gynecol Oncol
; 146(3): 484-490, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28698009
8.
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Gynecol Oncol
; 145(2): 236-242, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28341300
9.
A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gynecol Oncol
; 132(3): 526-30, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24361733
10.
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Gynecol Oncol
; 135(1): 25-33, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25019569
11.
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
Gynecol Oncol
; 129(3): 486-94, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23438670
12.
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Gynecol Oncol
; 127(1): 63-9, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22772063
13.
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gynecol Oncol
; 127(1): 70-4, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22710075
14.
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Gynecol Oncol
; 127(2): 345-50, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22885469
15.
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.
Gynecol Oncol
; 127(3): 456-61, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22960004
16.
Ovarian cancer, version 3.2012.
J Natl Compr Canc Netw
; 10(11): 1339-49, 2012 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23138163
17.
A phase II, single-arm study of the anti-α5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.
Gynecol Oncol
; 121(2): 273-9, 2011 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21276608
18.
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.
Gynecol Oncol
; 121(2): 303-8, 2011 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21329967
19.
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
Gynecol Oncol
; 123(1): 19-26, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21752435
20.
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Curr Probl Cancer
; 45(6): 100734, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33865615